ONESOURCE · NSE
Onesource Specialty Pharma Limited
₹1,609.3
+0.40% (+₹6.4)
Prev. close
₹1,602.9
Volume
1,78,590
Delivery %
57.8%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Onesource Industries And Ventures Ltd at ₹1,801.5, targeting ₹1,920, with a stop loss at ₹1,740, based…” | Sumeet BagadiaChoice Equity Broking | Onesource Industries And Ventures Ltd | PENDING | |
| “Initiates a Buy call on OneSource Specialty Pharma with a target price of Rs 2,049, expecting the stock to reach this le…” | JM Financial AnalysisJM Financial Institutional Securities | OneSource Specialty Pharma | HIT |
Fundamentals
About Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Singapore, the United States, Spain, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of pre-clinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed pens, and autoinjectors and self-administration platforms; sterile injectables; soft gelatin capsules; and biologics solutions for recombinant proteins, monoclonal antibodies and biosimilars, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Neeraj Sharma
Headquarters
Bengaluru
Employees
1,674
Website
onesourcecdmo.comExchange
View on NSE ↗Key stats
Market cap
₹18,159.80 Cr
Dividend yield
0.00%
EPS (TTM)
₹-0.15
Beta (1Y · daily vs NIFTY 50)
-0.12
Shares float
7.07 Cr
EPS · quarter ended Sept 2026
₹5.01
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
Left off as not meaningful (growth from a very small base, beyond ±400%): Sales FY25 (+740%), Trade receivables FY24 (+1345%), Trade receivables FY25 (+654%), Inventory FY25 (+1307%).
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
1 Revenue from operations | ₹171.92 Cr | ₹1,444.85 Cr | ₹1,421.59 Cr |
2 Other income | ₹4.23 Cr | ₹17.47 Cr | ₹15.02 Cr |
3 Total income (1+2) | ₹176.14 Cr | ₹1,462.33 Cr | ₹1,436.61 Cr |
| ₹425.90 Cr | ₹1,418.55 Cr | ₹1,518.65 Cr | |
5 Profit/(loss) before exceptional items and tax (3-4) | ₹-249.76 Cr | ₹43.78 Cr | ₹-82.03 Cr |
6 Exceptional items | ₹-115.94 Cr | — | — |
6 Exceptional items - gain / (loss) (net) | — | ₹-110.85 Cr | ₹-9.93 Cr |
7 Profit/(Loss) before tax (5+6) | ₹-365.70 Cr | ₹-67.07 Cr | ₹-91.96 Cr |
| — | ₹-49.79 Cr | ₹-18.16 Cr | |
9 Profit/(Loss) after tax from continuing operations (7-8) | ₹-365.70 Cr | ₹-17.28 Cr | ₹-73.80 Cr |
(i) Loss from discontinued operations | ₹-85.63 Cr | ₹-69.00 L | — |
(ii) Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net) | ₹60.16 Cr | — | — |
10 Profit/(Loss) after tax from discontinued operations | ₹-25.47 Cr | ₹-69.00 L | — |
11 Profit/(Loss) for the year (9+10) | ₹-391.17 Cr | ₹-17.97 Cr | ₹-73.80 Cr |
| ₹-53.10 L | ₹-3.18 Cr | ₹16.06 Cr | |
13 Total comprehensive income/(loss) for the year (11+12) | ₹-391.70 Cr | ₹-21.15 Cr | ₹-57.75 Cr |
Basic | -88.02 | -1.57 | -6.44 |
Diluted | -88.02 | -1.57 | -6.44 |
Basic | ₹-6.13 | ₹-0.06 | — |
Diluted | ₹-6.13 | ₹-0.06 | — |
Basic | ₹-94.15 | ₹-1.63 | ₹-6.44 |
Diluted | ₹-94.15 | ₹-1.63 | ₹-6.44 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹1,132.23 Cr | ₹6,464.06 Cr | ₹6,784.07 Cr | |
| ₹1,308.61 Cr | ₹7,550.24 Cr | ₹8,210.01 Cr | |
| ₹395.71 Cr | ₹5,880.58 Cr | ₹5,831.29 Cr | |
| — | ₹1,669.66 Cr | ₹2,378.73 Cr | |
| ₹282.31 Cr | ₹556.10 Cr | ₹936.76 Cr | |
| ₹630.59 Cr | ₹1,113.56 Cr | ₹1,441.97 Cr | |
Total Equity and liabilities (I+II) | ₹1,308.61 Cr | ₹7,550.24 Cr | ₹8,210.01 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹-107.21 Cr | ₹-67.85 Cr | ₹8.52 Cr | |
| ₹-107.21 Cr | ₹-201.08 Cr | ₹-494.98 Cr | |
| — | ₹165.36 Cr | ₹38.34 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|
| Promoter | 37.77% | 34.25% | 29.79% | 29.77% | 29.93% | 30.48% |
| Public | 62.23% | 65.75% | 70.21% | 70.23% | 70.07% | 69.52% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Onesource Specialty Pharma Limited | ₹17,954.53 Cr | ₹1,568.7 | — | 3.08 | -1.3% | 0.26 | -1.6% | -16.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
We Might See A Profit From OneSource Specialty Pharma Limited (NSE:ONESOURCE) Soon
OneSource Specialty Pharma Ltd reported a fiscal year loss of ₹738 million and a trailing‑twelve‑month loss of ₹16 million, narrowing its deficit as it moves toward breakeven. Four Indian life‑sciences analysts project the company will achieve breakeven in 2026 and generate about ₹4.6 billion profit in 2027, implying roughly 70% annual growth.
OneSource Pharma Q2 FY27 revenue up 37%
OneSource Specialty Pharma Limited reported a 37% year-on-year revenue increase and 53% EBITDA growth for Q2 FY27. The company's margins expanded to 32%, driven by new DDC capacity and strong performance in its semaglutide and biologics segments. They anticipate a stronger second half and reaffirmed their FY28 outlook.